{"id":562606,"date":"2021-09-10T13:16:02","date_gmt":"2021-09-10T13:16:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=562606"},"modified":"2021-09-10T13:16:02","modified_gmt":"2021-09-10T13:16:02","slug":"vasomotor-symptoms-of-menopause-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vasomotor-symptoms-of-menopause-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_562606.html","title":{"rendered":"Vasomotor Symptoms Of Menopause Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1631247797.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vasomotor Symptoms Of Menopause Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1631247797.png\" alt=\"Vasomotor Symptoms Of Menopause Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cVasomotor Symptoms of Menopause &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in the Vasomotor Symptoms of Menopause pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Vasomotor Symptoms Of Menopause Pipeline Insight<\/strong>&rdquo;<\/a> report provides comprehensive insights about key companies and pipeline drugs in the Vasomotor Symptoms Of Menopause pipeline landscapes.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report comprises <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Vasomotor Symptoms Of Menopause pipeline<\/a><\/strong> drug profiles, including clinical and non-clinical stage products. It also includes the Vasomotor Symptoms Of Menopause therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Vasomotor Symptoms Of Menopause pipeline products.&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c7766250a09bf93f7bb577abed0efa34.jpg\" alt=\"\" \/>&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the Vasomotor Symptoms Of Menopause Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Astellas Pharma, Nerre Therapeutics, Fervent Pharmaceuticals, Mithra Pharmaceuticals, etc., are developing therapies for the treatment of Vasomotor Symptoms Of Menopause.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies such as Fezolinetant, NT-814, FP-101, Donesta, are expected to have a significant impact on the &nbsp;Vasomotor Symptoms Of Menopause market in the coming years.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Vasomotor Symptoms Of Menopause Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Vasomotor Symptoms (Vasomotor Symptoms) are one of the major symptoms of menopause that principally include hot flashes (HF) and night sweats (NS) during menopause and occurs in the majority of women across the globe. A woman with Vasomotor Symptoms experiences abundant heat accompanied by sweating and flushing, especially around the head, neck, chest, and upper back region. Vasomotor Symptoms result from temperature dysfunction that occurs due to changes in gonadal hormones.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Fezolinetant by Astellas Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NT-814 by Nerre Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">FP-101 by Fervent Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Donesta by Mithra Pharmaceuticals,<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">And others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Scope of <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Vasomotor Symptoms Of Menopause Pipeline Drug Insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage: Global&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major Players: Astellas Pharma, Nerre Therapeutics, Fervent Pharmaceuticals, Mithra Pharmaceuticals, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline Therapies: Fezolinetant, NT-814, FP-101, Donesta, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause- Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Late Stage Products (Phase II\/III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Preclinical Stage Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Therapeutics Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>14<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>15<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>17<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>18<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Vasomotor Symptoms Of Menopause Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>19<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>20<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\">Get a customized pipeline report <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vasomotor-symptoms-of-menopause-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Vasomotor Symptoms Of Menopause Drugs Pipeline Report&nbsp; <\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vasomotor-symptoms-of-menopause-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vasomotor-symptoms-of-menopause-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cVasomotor Symptoms of Menopause &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 9+ companies and 9+ pipeline drugs in the Vasomotor Symptoms of Menopause pipeline landscape. It covers the pipeline drug profiles, including clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vasomotor-symptoms-of-menopause-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_562606.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-562606","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=562606"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/562606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=562606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=562606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=562606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}